Notice concerning commencement of Phase 1 clinical trial of an S1P receptor modulator “CP1050”March 12, 2018
TOKYO, March 12, 2018: Curadim Pharma Co., Ltd. announced today that it started Phase 1 clinical trial of a sphingosine-1-phosphate (S1P) receptor modulator “CP1050” in the UK.
CP1050 is a drug candidate in-licensed from Meiji Seika Pharma Co., Ltd. (its compound number: CP9531) in July 2016, developed for treating autoimmune diseases, such as multiple sclerosis. After in-licensing, we selected an active pharmaceutical ingredient (API) form and manufactured the investigational products. We also conducted the required non-clinical studies and the application for Medicines and Healthcare Products Regulatory Agency (MHRA), and thereby, we favorably started the Phase 1 clinical trial. This clinical trial is performed to examine safety and tolerability of CP1050 in healthy volunteers and will be completed by the end of 2018.